17th Jan 2022 15:16
(Alliance News) - Angle PLC announced on Monday that research undertaken by the University of Southern California Norris Cancer Centre has demonstrated the company's Parsortix-based liquid biopsy approach could replace invasive tissue biopsy.
The Surrey, England-based medical diagnostics company explained that the research demonstrated the potential of circulating tumour cells - harvested from a blood draw using the company's Parsortix system - to be used as an alternative to invasive tissue biopsy for metastatic breast cancer patients.
Angle explained that research reported a high degree of concordance between the Parsortix system and metastatic tissue samples, suggesting its potential as a surrogate method.
Parsortix involves a blood sample taken from a patient. It is then put through the Parsortix instrument where circulating tumour cells are caught. Once caught, the cells are stained with selected antibodies. This enables their identification and characterisation.
Shares in Angle were up 3.8% at 125.60 pence on Monday afternoon in London.
By Heather Rydings; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Angle